Publicaciones en colaboración con investigadores/as de Princess Margaret Cancer Centre (45)

2023

  1. Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program

    Annals of Epidemiology, Vol. 77, pp. 1-12

  2. How to Advance Palliative Care Research in South America? Findings From a Delphi Study

    Journal of Pain and Symptom Management, Vol. 65, Núm. 3, pp. 193-202

  3. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

    Annals of Oncology, Vol. 34, Núm. 1, pp. 48-60

  4. Overall Survival with Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial

    Journal of Clinical Oncology, Vol. 41, Núm. 8, pp. 1590-1599

  5. Overall Survival with Maintenance Olaparib at a 7-Year Follow-Up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

    Journal of Clinical Oncology, Vol. 41, Núm. 3, pp. 609-617

  6. Overall Survival with Maintenance Olaparib at a 7-Year Follow-up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

    Obstetrical and Gynecological Survey

2022

  1. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 1, pp. 24-33

  2. De Novo Malignancy after Liver Transplantation: Risk Assessment, Prevention, and Management - Guidelines from the ILTS-SETH Consensus Conference

    Transplantation, Vol. 106, Núm. 1, pp. E30-E45

  3. Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 7, pp. 483-494

  4. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer A Patient-Level Data Analysis of 3 Cohorts

    JAMA Oncology, Vol. 8, Núm. 3

  5. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study

    ESMO Open, Vol. 7, Núm. 5

  6. Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

    Blood cancer discovery, Vol. 3, Núm. 4, pp. 273-284

  7. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

    The Lancet Oncology, Vol. 23, Núm. 8, pp. 1055-1065

  8. The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study

    Cancers, Vol. 14, Núm. 3

2021

  1. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

    Future Oncology, Vol. 17, Núm. 16, pp. 1987-2003

  2. Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial

    ESMO Open, Vol. 6, Núm. 2

  3. Challenges and novel opportunities of radiation therapy for brain metastases in non-small cell lung cancer

    Cancers, Vol. 13, Núm. 9

  4. Idecabtagene vicleucel in relapsed and refractory multiple myeloma

    New England Journal of Medicine, Vol. 384, Núm. 8, pp. 705-716

  5. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma

    Blood Cancer Journal, Vol. 11, Núm. 6

  6. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet Oncology, Vol. 22, Núm. 12, pp. 1721-1731